Expert opinion on the management of renal manifestations of chronic HCV infection

Fabrizio Fabrizi, Francesco Negro, Mark Bondin, Patrice Cacoub

Research output: Contribution to journalArticle

Abstract

Chronic HCV infection is a non-traditional (but modifiable) risk factor for chronic kidney disease and has been implicated in glomerular injury and nephrosclerotic disease. Three HCV direct-acting antiviral regimens are available for patients with severe kidney impairment: ombitasvir, paritaprevir with the pharmacokinetic enhancer ritonavir, and dasabuvir; glecaprevir plus pibrentasvir; and elbasvir plus grazoprevir. In patients with severe kidney impairment, sofosbuvir-free regimens are preferred because sofosbuvir accumulation has been associated with a progressive worsening of renal function. In this Review, we provide our expert opinion on the current HCV treatment paradigm and highlight the remaining issues that need to be overcome to improve the treatment of HCV in this population.

Original languageEnglish
Pages (from-to)57-67
Number of pages11
JournalAntiviral Therapy
Volume23
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Expert Testimony
Kidney
Infection
Ritonavir
Chronic Renal Insufficiency
Antiviral Agents
Pharmacokinetics
Wounds and Injuries
Therapeutics
Population
Sofosbuvir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Expert opinion on the management of renal manifestations of chronic HCV infection. / Fabrizi, Fabrizio; Negro, Francesco; Bondin, Mark; Cacoub, Patrice.

In: Antiviral Therapy, Vol. 23, 01.01.2018, p. 57-67.

Research output: Contribution to journalArticle

Fabrizi, Fabrizio ; Negro, Francesco ; Bondin, Mark ; Cacoub, Patrice. / Expert opinion on the management of renal manifestations of chronic HCV infection. In: Antiviral Therapy. 2018 ; Vol. 23. pp. 57-67.
@article{8757c9b19ff74f39a342dcafb35addd7,
title = "Expert opinion on the management of renal manifestations of chronic HCV infection",
abstract = "Chronic HCV infection is a non-traditional (but modifiable) risk factor for chronic kidney disease and has been implicated in glomerular injury and nephrosclerotic disease. Three HCV direct-acting antiviral regimens are available for patients with severe kidney impairment: ombitasvir, paritaprevir with the pharmacokinetic enhancer ritonavir, and dasabuvir; glecaprevir plus pibrentasvir; and elbasvir plus grazoprevir. In patients with severe kidney impairment, sofosbuvir-free regimens are preferred because sofosbuvir accumulation has been associated with a progressive worsening of renal function. In this Review, we provide our expert opinion on the current HCV treatment paradigm and highlight the remaining issues that need to be overcome to improve the treatment of HCV in this population.",
author = "Fabrizio Fabrizi and Francesco Negro and Mark Bondin and Patrice Cacoub",
year = "2018",
month = "1",
day = "1",
doi = "10.3851/IMP3247",
language = "English",
volume = "23",
pages = "57--67",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",

}

TY - JOUR

T1 - Expert opinion on the management of renal manifestations of chronic HCV infection

AU - Fabrizi, Fabrizio

AU - Negro, Francesco

AU - Bondin, Mark

AU - Cacoub, Patrice

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Chronic HCV infection is a non-traditional (but modifiable) risk factor for chronic kidney disease and has been implicated in glomerular injury and nephrosclerotic disease. Three HCV direct-acting antiviral regimens are available for patients with severe kidney impairment: ombitasvir, paritaprevir with the pharmacokinetic enhancer ritonavir, and dasabuvir; glecaprevir plus pibrentasvir; and elbasvir plus grazoprevir. In patients with severe kidney impairment, sofosbuvir-free regimens are preferred because sofosbuvir accumulation has been associated with a progressive worsening of renal function. In this Review, we provide our expert opinion on the current HCV treatment paradigm and highlight the remaining issues that need to be overcome to improve the treatment of HCV in this population.

AB - Chronic HCV infection is a non-traditional (but modifiable) risk factor for chronic kidney disease and has been implicated in glomerular injury and nephrosclerotic disease. Three HCV direct-acting antiviral regimens are available for patients with severe kidney impairment: ombitasvir, paritaprevir with the pharmacokinetic enhancer ritonavir, and dasabuvir; glecaprevir plus pibrentasvir; and elbasvir plus grazoprevir. In patients with severe kidney impairment, sofosbuvir-free regimens are preferred because sofosbuvir accumulation has been associated with a progressive worsening of renal function. In this Review, we provide our expert opinion on the current HCV treatment paradigm and highlight the remaining issues that need to be overcome to improve the treatment of HCV in this population.

UR - http://www.scopus.com/inward/record.url?scp=85056700673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056700673&partnerID=8YFLogxK

U2 - 10.3851/IMP3247

DO - 10.3851/IMP3247

M3 - Article

C2 - 30451153

AN - SCOPUS:85056700673

VL - 23

SP - 57

EP - 67

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

ER -